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Oncogene-induced senescence (OIS) is a potent tumor suppressor mechanism. To identify senescence regulators
relevant to cancer, we screened an shRNA library targeting genes deleted in hepatocellular carcinoma (HCC). Here,
we describe how knockdown of the SWI/SNF component ARID1B prevents OIS and cooperates with RAS to induce
liver tumors. ARID1B controls p16INK4a and p21CIP1a transcription but also regulates DNA damage, oxidative stress,
and p53 induction, suggesting that SWI/SNF uses additional mechanisms to regulate senescence. To systematically
identify SWI/SNF targets regulating senescence, we carried out a focused shRNA screen. We discovered several new
senescence regulators, including ENTPD7, an enzyme that hydrolyses nucleotides. ENTPD7 affects oxidative stress,
DNAdamage, and senescence. Importantly, expression of ENTPD7 or inhibition of nucleotide synthesis inARID1B-
depleted cells results in re-establishment of senescence. Our results identify novelmechanisms bywhich epigenetic
regulators can affect tumor progression and suggest that prosenescence therapies could be employed against SWI/
SNF-mutated cancers.
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The extensive sequencing of cancer genomes has provided
a comprehensive list of the recurrent genetic alterations
observed in different tumor types. In addition to well-
known oncogenes and tumor suppressors, these studies
have linked unforeseen candidates to cancer (Watson
et al. 2013). In parallel, our overall understanding of cancer
biology has advanced considerably, and specific hallmarks
have been proposed to explain the diversity of cancer
(Hanahan and Weinberg 2011). However, despite progress
in both areas, the explanation for the functional signifi-
cance that recurring genetic alterations have in cancer
progression is often missing but is much needed to
develop targeted therapies.
Bypass of senescence is a common characteristic of ad-
vanced tumors (Narita and Lowe 2005). In response to on-
cogenic signaling, cells activate a stress response termed
oncogene-induced senescence (OIS). OIS is a feature of
premalignant lesions and has an important role in tumor
suppression (Collado and Serrano 2010). Consequently,
advanced tumors almost invariably escape senescence,
and this constitutes one of the hallmarks of cancer
(Hanahan and Weinberg 2011). A well-studied example
is hepatocellular carcinoma (HCC). Aberrant oncogenic
activation in hepatocytes activates OIS, which in turn
limits HCC generation via cell-intrinsic and cell-extrinsic
mechanisms (Kang et al. 2011). Overall, OIS is a complex
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program that includes the implementation of a highly sta-
ble cell cycle arrest but also profound changes in transcrip-
tion, metabolism, secretome, and chromatin organization
(Kuilman et al. 2010). Many of these senescent pheno-
types are under epigenetic control (Kia et al. 2008; Barra-
das et al. 2009). Interestingly, a major discovery from
cancer genome studies is that chromatin modifiers are of-
ten mutated in cancer (Plass et al. 2013). In particular,
genes encoding for components of the SWI/SNF chroma-
tin remodeling complex are frequently deleted ormutated
across a wide spectrum of cancers (Kadoch et al. 2013).
This suggests that SWI/SNF plays a fundamental protec-
tive role toward tumorigenesis via the regulation of basic
cellular functions. Whether the frequency of these alter-
ations relates to the ability of the SWI/SNF complex to
control senescence is an enticing possibility.
The SWI/SNF complexes reposition nucleosomes and
bind to DNA regulatory regions to control transcription.
Loss-of-function mutations of different SWI/SNF compo-
nents drive tumorigenesis by disrupting gene expression
(Wilson and Roberts 2011). SWI/SNF are macromolecu-
lar complexes comprising 12–15 subunits: A catalytic
ATPase subunit, SMARCA4/BRG1 or SMARCA2/BRM,
and several core subunits, such as SMARCB1/SNF5/
INI1/BAF47 or SMARCC1/BAF155, are common to all
SWI/SNF complexes. Other subunits, such as ARID1A
and ARID1B, are mutually exclusive components of BAF
(BRG1-associated factor) complexes, while PBRM1 and
ARID2 are specific for PBAF (polybromo BAF) complexes
(Helming et al. 2014a).
Many components of SWI/SNF complexes are altered
in different malignancies, adding up to a global ∼20% of
cancers bearing mutations in SWI/SNF genes (Kadoch
et al. 2013). The BAF subunit ARID1A has the highest
mutation rate among SWI/SNF components (Helming
et al. 2014a). Mutations in its paralog, ARID1B, are less
frequent but have also been observed in melanoma, gas-
tric cancer, colorectal cancer, HCC, neuroblastoma, and
pancreatic cancer (Fujimoto et al. 2012; Khursheed et al.
2013; Sausen et al. 2013; Lee et al. 2015). In HCC, >20%
of the tumors present alterations in SWI/SNF compo-
nents, and mutations in ARID1B are second only to
ARID1A in frequency (Fujimoto et al. 2012).
Given the prevalence of SWI/SNF mutations, several
studies have investigated themolecularmechanisms link-
ing SWI/SNF disruption with cancer progression. SWI/
SNF components have been reported to interact with
RB (Trouche et al. 1997), MYC (Cheng et al. 1999), or
p53 (Lee et al. 2002). Moreover, inactivation of the SWI/
SNF complex due to loss of specific components such as
SNF5, BRD7, or PBR1 results in senescence bypass (Oruet-
xebarria et al. 2004; Burrows et al. 2010; Drost et al. 2010).
Direct transcriptional regulation of p16INK4a (Oruetxebar-
ria et al. 2004; Kia et al. 2008) or p21CIP1 (Chai et al. 2005)
by SWI/SNF complexes might explain, in part, their role
in senescence. However, a more comprehensive explana-
tion of how SWI/SNF regulates senescence and how this
is relevant for tumorigenesis is still lacking.
In this investigation, we carried out a functional screen
to identify HCC-deleted genes regulating senescence. We
found that depletion of ARID1B blunted the senescence
response and cooperated with oncogenic Ras in HCC for-
mation. By systematically investigating ARID1B target
genes, we discovered several novel mediators of senes-
cence, among them ENTPD7, an enzyme involved in nu-
cleotide metabolism. Overall, the identification of novel
mechanisms by which ARID1B loss restricts senescence
could reveal vulnerabilities (e.g., nucleotide metabolism)
useful to target cancers bearing mutations in SWI/SNF
genes.
Results
An shRNA screen identifies Arid1b as a regulator
of senescence
Senescence is a potent tumor suppressor mechanism
(Kuilman et al. 2010) often disabled in cancer cells (Hana-
han andWeinberg 2011). For example, induction of senes-
cence in preneoplastic hepatocytes actively prevents
HCC (Kang et al. 2011). To identify tumor suppressors
that control senescence and could limit liver cancer, we
devised a genetic screen using an shRNA library targeting
genes frequently deleted in HCC (Zender et al. 2008). We
carried out the screen in mouse embryonic fibroblasts
(MEFs), which are a robust systemused previously to iden-
tify regulators of senescence (Jacobs et al. 2000; Kondoh
et al. 2005). MEFs were infected with the shRNA library,
selected, and passaged regularly until controls underwent
senescence (Fig. 1A; Supplemental Fig. S1A). The relative
distribution of shRNAs during the screen was determined
using next-generation sequencing (NGS). We then used
statistical analysis to identify shRNAs significantly en-
riched inMEFs bypassing senescence (Fig. 1B; Supplemen-
tal Fig. S1B). Among the enriched shRNAs, two targeted
the SWI/SNF subunit Arid1b (including the top shRNA
enriched in the screen) (Fig. 1B; Supplemental Fig. S1B).
Since SWI/SNF components are frequently mutated or
deleted in cancer (Oruetxebarria et al. 2004; Shain and
Pollack 2013), we decided to confirm that Arid1b knock-
down prevented senescence using two shRNAs target-
ing murine Arid1b (Fig. 1C; Supplemental Fig. S1C,D).
Similar to what we observed when using an shRNA tar-
geting Ink4a/Arf (shp16/Arf) (Supplemental Fig. S1C),
knockdown of Arid1b blunted replicative senescence,
as evidenced by increased colony formation, a higher per-
centage of cells incorporating BrdU, and a decrease in
the percentage of senescence-associated β-galactosidase
(SA-β-Gal)-positive cells when compared with control
MEFs (Fig. 1C). Additionally, we tested whether knock-
down of Arid1b expression protected MEFs against senes-
cence induced by oncogenic RAS. While MEFs expressing
RASG12V underwent premature senescence, MEFs infect-
ed with shRNAs targeting Arid1b or p53 continued to pro-
liferate (Supplemental Fig. S1E). Moreover, the cells grew
anchorage-independently, as assessed by soft agar assay,
indicating oncogenic cooperation between RASG12V and
Arid1b knockdown (Fig. 1D). Altogether, these results
suggest that knockdown of Arid1b enables bypass of sen-
escence in MEFs.
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Knockdown of Arid1b cooperates in HCC generation
by blunting OIS
Next, we investigated whether Arid1b depletion can pre-
vent senescence in vivo and in this way contribute to liver
cancer development. To test this, we used a mouse model
in which OIS is triggered in hepatocytes via transposon-
mediated transfer of oncogenic Nras (NrasG12V) delivered
by hydrodynamic tail vein (HDTV) injection (Fig. 2A;
Kang et al. 2011). In thismodel, the senescent hepatocytes
activate an immune response that results in their gradual
elimination (Kang et al. 2011). To investigate whether
Arid1b knockdown affects OIS in vivo, we coexpressed
NrasG12V and either control or Arid1b targeting shRNAs.
We measured Arid1b levels in NrasG12V-expressing hepa-
tocytes 9 d after transposon injection. Hepatocytes ex-
pressing an inactive variant (NrasG12V,D38A) displayed
lower levels of Arid1b than those carrying the constitu-
tively active variant (NrasG12V), indicating that oncogenic
NrasG12V induces Arid1b expression during senescence in
vivo. Furthermore, both shRNAs targetingArid1b blunted
its induction (Fig. 2B; Supplemental Fig. S2A,B). We next
evaluated the consequences of depleting Arid1b in Nras-
expressing hepatocytes. At day 9, there were more Nras-
positive hepatocytes present in the livers of mice trans-
duced with NrasG12V_shArid1b than NrasG12V_ shCTR
vectors (Fig. 2C,D). Thehigher percentage ofNras+ hepato-
cytes correlated with reduced senescence, as shown by de-
creased levels of SA-β-Gal in the livers of mice transduced
with NrasG12V_shArid1b vectors. In addition, a lower per-
centage ofNras-positivehepatocyteswere also positive for
p21Cip1a or p16Ink4a upon Arid1b depletion (Fig. 2C,D).
Other SWI/SNF components have been suggested to
control senescence by regulating p21Cip1a or p16Ink4a tran-
scription (Chai et al. 2005). Interestingly, we also observed
a decreased DNA damage response (DDR; assessed by
53BP1 staining) in Nras+ hepatocytes of mice transduced
with NrasG12V_shArid1b vectors (Fig. 2E; Supplemental
Fig. S2C), suggesting that theremight be additional mech-
anisms by which Arid1b and, by extension, the SWI/SNF
complex control senescence.
Nras+ hepatocytes in which Arid1b expression was
knocked down also proliferated more, displaying a higher
percentage of Ki67+ cells (Fig. 2F; Supplemental Fig. S2D).
Since depletion of Arid1b blunted the senescence re-
sponse in vivo and resulted in higher percentages of prolif-
erating Nras+ hepatocytes, we investigated whether the
knockdown of Arid1b cooperated with NrasG12V in tumor
Figure 1. An shRNA screen identifies the SWI/SNF subunit ARID1B as a regulator of senescence. (A) Schematic model of the bypass of
senescence screen using a library of shRNAs targeting genes deleted in HCC. An average of two different shRNAs per gene were used.
MEFs were infected with the shRNA library or controls and passaged until vector cells reached senescence. shRNAs that extended life
span were recovered by NGS. The screen was performed in triplicate. (B) List of significantly enriched shRNAs by Fisher’s combined
P-value (P < 0.001). shRNAs targeting ARID1B are marked in red. (C ) Representative images of ARID1B, BrdU, SA-β-Gal immunofluores-
cence (IF) staining, and colony formation assay (crystal violet) of MEFs transduced with shRNAs targeting ARID1B, p16INK4a, or empty
vector. DAPI was used to visualize the nuclei. Bar, 30 μm. Quantification of IF by high-content analysis (HCA) is shown at the right.
(D) Soft agar assay ofMEFs transducedwithRasG12V cDNAand either an empty vector or vectors carrying shRNAs for p16/Arf or ARID1B.
Representative images at 4× magnification (left) and quantification (right) are shown. Graphs in C and D represent mean ± SD from n = 4
and n = 3, respectively. (∗∗∗) P < 0.001 by two-tailed Student t-test.
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formation. To test this, we used a protocol similar to that
used before and monitored the mice regularly for tumor
formation (Fig. 2G, left). While only one out of 10 mice
injected with the NrasG12V_shCTR vector died of tumors
during the time they were monitored, eight out of 13 of
those bearing the NrasG12V_shArid1b.1 construct suc-
cumbed to HCCs (Fig. 2G, middle). Fluorescence imaging
confirmed that these tumors derived from hepatocytes
expressing the transduced vectors, as they were GFP-pos-
itive (Fig. 2G, right). Altogether, these results indicate
that knockdown of Arid1b contributes to HCC formation
by blunting senescence.
ARID1B regulates OIS in human fibroblasts
To investigate themechanism bywhich ARID1B controls
senescence in more detail, we took advantage of IMR90
human fibroblasts, as they are a widely used system to
study senescence and are amenable tomechanistic dissec-
tion. First, we checked whether ARID1B is necessary
for the implementation of senescence in human cells.
To this end, we generated two shRNAs to target human
ARID1B (Supplemental Fig. S3A,B) and used them to in-
fect IMR90 human fibroblasts expressing ER:RAS
(IMR90 ER:RAS), an inducible model of OIS. Depletion
of ARID1B in IMR90 ER:RAS cells blunted OIS, as evi-
denced by increased proliferation and a decrease in the
percentage of cells positive for SA-β-Gal (Fig. 3A). To in-
vestigate how the depletion of ARID1B affects OIS, we
performed transcriptional profiling of IMR90 ER:RAS
cells infected with an shRNA targeting ARID1B (Fig. 3B,
left). Using gene set enrichment analysis (GSEA), a signa-
ture of OIS was found significantly down-regulated upon
ARID1B knockdown (Fig. 3B, middle). GSEA and Ingenu-
ity Pathway Analysis (IPA) showed that SWI/SNF
(SMARCA4) target genes were induced during OIS, and
Figure 2. Knockdown of Arid1b alleviates OIS in vivo and cooperates in HCC formation. (A) Scheme of the in vivo senescence experi-
ments. Transposon constructs carryingNrasG12V cDNAandArid1b shRNAs (or control) were delivered intomouse livers by hydrodynam-
ic injection (NrasG12V/D38A was used as negative control). n = 4 mice per condition were used. (B) Quantification of Arid1b nuclear IF
staining in Nras+ mouse hepatocytes in the above-described conditions is shown. (C ) Representative pictures of immunohistochemistry
(IHC) for Nras, SA-β-Gal staining, and IF staining for p21CIP1 and p16INK4a on liver sections frommice injected with the indicated vectors.
(D–F ) Quantification of the SA-β-Gal staining and percentages of Nras-positive, p16INK4a-positive, or p21CIP1-positive cells (D) and 53bp1-
positive (E) or Ki67-positive (F ) cells in liver sections frommice injectedwith the indicated vectors.Graphs representmean ± SD fromn = 4
mice. (∗∗∗) P < 0.001; (∗∗) P < 0.01; (∗) P < 0.05; (n.s.) nonsignificant by two-tailed Student t-test. (G, left) Scheme of the in vivo tumor growth
experiment. Transposon constructs carrying NrasG12V cDNA and an Arid1b shRNA (or control) were delivered into mouse livers by hy-
drodynamic injection.Miceweremonitored for 30wk. n = 10 shCTR and n = 13 shArid1b.1micewere used. Kaplan-Meier survival curves
(middle) and representative pictures of livers (right) showing GFP-positive tumor nodules as they were derived from the injected con-
structs. (∗) P < 0.05 by log rank (Mantel-Cox) test. Bar, 100 μm. DAPI was used to visualize the nuclei.
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this induction was blunted by ARID1B knockdown (Fig.
3B, right; data not shown). Interestingly, IPA also suggest-
ed that ARID1B depletion prevented the activation of the
p53 pathway and oxidative stress observed duringOIS (Fig.
3B, right). Key effectors of senescence such as p16INK4a
and p21CIP1 were down-regulated at both the mRNA and
protein level upon ARID1B depletion (Fig. 3C,D; Supple-
mental Fig. S3C). Consistent with the observations in
vivo, depletion of ARID1B resulted in reduced DDR (Fig.
3C,D). In addition, confirming the IPA, ARID1B knock-
down resulted in decreased levels of p53 and oxidative
stress (as measured by 8-oxodG staining) (Fig. 3C,D).
ARID1B expression triggers a senescent-like arrest
To complement the knockdown studies, we analyzed the
effect of expressing ARID1B in IMR90 cells. Expression of
ARID1B in IMR90 cells induced growth arrest, SA-β-Gal
activity, and a decrease in the percentage of BrdU-positive
cells (Fig. 4A; Supplemental Fig. S4A). By analyzing the
transcriptional profiles of IMR90 cells infectedwith a con-
trol vector or ARID1B byGSEA,we observed thatARID1B
overexpression was associated with signatures of OIS
and senescence-related phenotypes such as SASP and
cell cycle arrest (Supplemental Fig. S4B). IPA confirmed
that ARID1B expression resulted in the up-regulation of
SWI/SNF target genes and the induction of the DDR and
p53 (Fig. 4B,C). Indeed, the expression of ARID1B not
only induced p16INK4a and p21CIP1a but also up-regulated
p53 levels and caused DNA damage and oxidative stress
(Fig. 4D,E). We then interrogated the relative contribution
of these pathways to the ARID1B-mediated arrest using
shRNAs. The arrest caused by ARID1B was prevented
partially when the expression of p16INK4a or p21CIP1a had
been knocked down (Fig. 4F; Supplemental Fig. S4C).
Interestingly, knocking down p53 prevented to a larger
extent the arrest caused by ARID1B expression (Fig. 4F),
suggesting an important role of the p53 pathway in
ARID1B-mediated arrest. Altogether, these observations
reinforce the idea that, in addition to regulating p16INK4a
and p21CIP1 transcription, ARID1B uses additional mech-
anisms, such as the generation of p53-activating stress sig-
nals (DDR and oxidative stress), to control senescence.
Identification of novel ARID1B targets controlling
senescence
To identify novel mechanisms by which ARID1B and, by
extension, the SWI/SNF complex regulate senescence,
we generated an shRNA library targeting 255 genes up-
Figure 3. ARID1B regulates OIS in human
cells. (A) IMR90 ER:RAS cells were trans-
duced with either an empty vector (vec), a
p53 shRNA (shp53), or ARID1B shRNAs
(shARID1B.2 [shA2] and shARID1B.3
[shA3]) and induced to undergo senescence
by 4OHT treatment. Cell proliferation was
assessed by crystal violet staining (top left)
and BrdU incorporation (right). Senescence
was measured by SA-β-Gal staining (repre-
sentative pictures are at the bottom left, and
quantification is at the right). (B, left)
IMR90 ER:RAS cells transduced with an
empty vector (±4OHT) or ARID1B shRNAs
(+4OHT)were subjected to globalmRNAex-
pression analysis. Data were subjected to
GSEA and IPA. n = 3 biological replicates
were used. (Middle) GSEA showing loss of a
signature associatedwithOIS in the gene ex-
pressionprofileof IMR90ER:RASshARID1B
versus empty vector, both 4OHT-treated.
(NES)Normalizedenrichedscore;(FDR)false
discovery rate. (Right) IPA upstream regula-
tor analysis of the indicated comparisons is
shown. The predicted activation (z-score) of
SMARCA4, TP53, and reactive oxygen spe-
cies (ROS) pathways is shown. (C,D) Quanti-
fication by HCA (D) of IF staining (C ) for
p21CIP1, p16INK4a, p53, γH2AX, and 8-oxodG
in IMR90 ER:RAS cells transduced with ei-
ther an empty vector or an shRNA targeting
ARID1B (±4OHT). DAPI was used to visual-
ize the nuclei. Graphs represent mean ± SD
from n = 4 (A, BrdU) and n = 3 (A [SA-β-Gal],
D). (∗∗∗) P < 0.001; (∗∗) P < 0.01; (∗) P < 0.05 by
two-tailed Student t-test. Bars, 30 μm.
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regulated during OIS. It included a subset of ARID1B-
dependent genes based on our gene expression analysis
(Supplemental Fig. S5A). We designed up to six shRNAs
targeting each gene and cloned the library in amiRE-based
vector that has improved knockdown efficiency when
compared with other shRNA vectors (Fellmann et al.
2013). Using this library, we carried out a screen for bypass
of OIS in IMR90 ER:RAS cells (Fig. 5A; Supplemental Fig.
S5B). After infection with the library or controls, senes-
cence was induced by adding 4OHT to activate ER:RAS,
and cells were passaged until growth (indicative of senes-
cence bypass) was observed in library-infected plates. The
distribution of shRNAs at different time points was calcu-
lated byNGS. Importantly, by including up to six shRNAs
targeting each gene in the library, wewere able to analyze
the results of the screen at the gene level rather than the
shRNA level. Statistical analysis using EdgeR unveiled
14 genes whose shRNAs were significantly enriched
(P < 0.001) in cells bypassing OIS. Interestingly, 13 of the
14 candidates identified in the screen were ARID1B-de-
pendent genes (Supplemental Fig. S5C). Using IPA, we in-
dependently confirmed a significant enrichment for SWI/
SNF (SMARCA4) target genes among the top hits of the
screen (Supplemental Fig. S5D) and for genes related to
p53 and reactive oxygen species (ROS) (Supplemental
Fig. S5D). The top gene identified in the screen was
CDKN1A (Fig. 5B; Supplemental Fig. S5E), which encodes
for p21CIP1, a key senescence regulator. Our data and the
literature (Chai et al. 2005) support an important role
for p21CIP1a in implementing SWI/SNF-mediated senes-
cence. This served as an internal control and confirmed
the validity of our approach. Among the other genes iden-
tified, at least three (SLC31A2, ENTPD7, and NDST2)
could be functionally associated with the generation of
oxidative stress or DDR. We confirmed that these three
genes were SWI/SNF targets induced during OIS (Supple-
mental Fig. S5F–H). To investigate the role of SLC31A2,
NDST2, and ENTPD7 in OIS, we generated two shRNAs
targeting each gene (Supplemental Fig. S6A). Knocking
down either ENTPD7, SLC31A2, or NDST2 in IMR90
Figure 4. Ectopic expression of ARID1B induces senescence. (A,D,E) IMR90 cells were transducedwith either an empty vector,ARID1B
cDNA, or RasG12V cDNA and then analyzed for cell growth (crystal violet), SA-β-Gal activity, and BrdU incorporation (A) as well as IF
staining (D) using the indicated antibodies. DAPI was used to visualize the nuclei. (E) Quantification by HCA of IF staining in D. Data
represent mean ± SD from n = 3 (A, SA-β-Gal) and n = 4 (A [BrdU], E). (B) RNA sequencing (RNA-seq) was performed with IMR90 cells
transduced with either an empty vector or ARID1B cDNA. Data were subjected to GSEA and IPA. n = 3 biological replicates were
used. (C ) IPA upstream regulator analysis of the RNA-seq reveals activation (z-score) of SMARCA4, TP53, and ROS pathways. (F )
IMR90 cellswere cotransducedwith an empty vector orARID1B cDNAand shRNAs targeting p21CIP1, p16INK4a, or p53. Cell proliferation
was assessed by crystal violet staining. (∗∗∗) P < 0.001; (∗∗) P < 0.01 by two-tailed Student t-test. Bars, 30 μm.
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ER:RAS cells did not affect the strength of RAS/ERK acti-
vation (Supplemental Fig. S6B) but prevented the senes-
cent arrest (Fig. 5C,D) and blunted p21CIP1a induction
(Fig. 5E). Similarly, depletion of ENTPD7, SLC31A2, or
NDST2 partially prevented the senescent arrest caused
by ARID1B expression (Supplemental Fig. S6C,D). These
results confirm the identification of novel mediators of
the effects of ARID1B in OIS.
Multiple ARID1B target genes mediate induction
of OIS in the liver
We next analyzed whether the ARID1B targets identified
in the screen have a role inmediatingOIS in vivo. First, we
tested whether they were induced in livers transduced
with oncogenic Nras (NrasG12V). We observed an increase
in Entpd7, Slc31a2, and Ndst2 expression by NrasG12V in
an Arid1b-dependent fashion (Fig. 6A; Supplemental Fig.
S7A), suggesting that the coordinated regulation of multi-
ple SWI/SNF-dependent genes could mediate the effects
of Arid1b on senescence.
To test this, we examined whether Entpd7 and Slc31a2
mediate OIS in vivo. We focused on these two genes
because they are down-regulated in a large subset of
humanHCCs (Supplemental Fig. S7B), and their depletion
blunted senescence strongly in vitro. We transduced mice
with vectors coexpressing oncogenic Nras (NrasG12V) and
a control shRNA or shRNAs targeting Arid1b, Entpd7, or
Slc31a2 (Fig. 6B, left). Knockdown of Entpd7 or Slc31a2 re-
sulted in increased numbers of Nras+ hepatocytes 6 d after
transduction (Fig. 6B, middle; Supplemental Fig. S7C).
Moreover, knocking down Entpd7 or Slc31a2 led to an in-
crease in the proportion of Nras+ hepatocytes that were
proliferating, suggesting bypass of senescence (Fig. 6B,
right). However, the effects observed upon depletion of ei-
ther Entpd7 or Slc31a2 were not as pronounced as those
observed upon Arid1b depletion (Fig. 6B), perhaps because
Arid1b regulates multiple targets to control senescence.
To explore this hypothesis, we devised a modified ver-
sion of theHDTV injection assay that combined transduc-
tion of two transposon vectorswith themore active SB100
transposase to make possible the simultaneous down-reg-
ulation of two genes (Fig. 6C). We tested the effect that
the combined knockdown of Entpd7 and Slc31a2 had on
OIS of hepatocytes in vivo by comparing the results
with knockdown of Arid1b (Fig. 6D; Supplemental Fig.
Figure 5. A focused shRNA screen identified novel ARID1B effectors controlling senescence. (A) Schematic model of the bypass of sen-
escence screen using a library of shRNAs targeting genes up-regulated in OIS, including some that are ARID1B-dependent. An average of
six different shRNAs per genewere used.After infectionwith the shRNA library or controls, IMR90ER:RAS cellswere treatedwith 4OHT
and passaged until library-infected cells bypassed senescence. shRNAs that bypassed senescencewere recovered byNGS. The screen was
performed in duplicate. (B) List of significantly enriched genes by Fisher’s combined P-value (P < 0.001). CDKN1A and genes selected for
further analysis aremarked in red. (C–E) Colony formation assay (C ), BrdU incorporation (D), and p21 analysis (E) of IMR90 cotransduced
with RASG12V (or empty vector) and shRNAs for ENTPD7 (shE2 and shE3), SLC31A2 (shS1 and shS2), or NDST2 (shN1 and shN2). A p53
shRNAwas used as control. Quantifications of IF stainingwere performed byHCA. n = 3. Graphs representsmean ± SD. (∗∗∗) P < 0.001; (∗∗)
P < 0.005; (∗) P < 0.05 by two-tailed Student t-test.
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S7D). In this assay, individual knockdown of Entpd7 or
Slc31a2 caused a modest increase in the percentage of
Nras+ hepatocytes present 9 d after transduction. There
was a clearer increase in the percentage of proliferating
Ki67+/Nras+ hepatocytes upon individual knockdown of
Entpd7 or Slc31a2, but it was not comparable with that
observed upon Arid1b knockdown in the same setting
(Fig. 6D). Interestingly, the combined depletion of Entpd7
and Slc31a2 resulted in an increased proportion of Nras+
and Ki67+/Nras+ hepatocytes, comparable with that ob-
served upon Arid1b knockdown (Fig. 6D). A similar trend
was observed when analyzing senescence by SA-β-Gal
staining. The combined knockdown of Entpd7 and
Slc31a2 resulted in a significant decrease of senescence
similar to that achieved upon Arid1b down-regulation
(Fig. 6D). Overall, these results confirm that ARID1B con-
trols senescence by coordinating the regulation of multi-
ple targets.
Nucleotide metabolism is a potential liability
of ARID1B mutant tumors
Given the prominent tumor suppressor role of senes-
cence, strategies aimed to reactivate senescence in tumors
(so-called prosenescence therapies) have been explored to
target cancer (Nardella et al. 2011; Acosta and Gil 2012).
As depletion of ARID1B prevents senescence, we postu-
lated that senescence reactivation could be used to target
SWI/SNFmutant tumors. Among theARID1B targetsme-
diating senescence, ENTPD7 was of particular relevance,
as it is an enzyme involved in nucleotide catabolism (Shi
et al. 2001). Shortage of deoxyribonucleotides (dNTPs)
has been shown previously to cause OIS via activation
of DDR (Aird et al. 2013). Interestingly, a significant corre-
lation exists between the expression levels of ENTPD7
and ARID1B in several cancer types, including liver can-
cer (Supplemental Fig. S8A,B). Moreover, when HCC cas-
es were stratified according to the mutational status of
ARID1B or the SWI/SNF complex, we observed signifi-
cantly lower ENTPD7 expression in the mutated samples
(Fig. 7A).
Ectopic expression of ENTPD7 in IMR90 cells caused
growth arrest and senescence (Fig. 7B,C). ENTPD7 ex-
pression induced several senescent effectors—including
p16INK4a but more significantly p53 and p21CIP1a—and
increased DNA damage (Fig. 7D). ENTPD7 belongs to
the ENTPD family of ectonucleoside triphosphate diphos-
phohydrolases. Despite the name, membrane topology
Figure 6. ARID1B controls senescence by
coordinated regulation of multiple targets.
(A) NrasG12V or NrasG12V/D38A transposon
constructs were delivered intomouse livers
by hydrodynamic injection. Livers were
harvested after 6 d, followed by mRNA ex-
traction and quantitative RT–PCR analysis
for Entpd7, Slc31a2, andNdst2mRNA lev-
els. n = 6 mice per condition were used. (B)
Transposon constructs carrying NrasG12V
cDNA and Arid1b shRNAs (shSL.1 and
shSL.2) or control (shCTR) were delivered
into mouse livers by hydrodynamic injec-
tion. n = 4 mice per condition were used.
Liverswere harvested after 6 d, and sections
were stained for Nras and Ki67. Quantifica-
tion of IF staining is shown at the right.
Graphs represent mean ± SD. (∗∗∗) P <
0.001; (∗∗) P < 0.005; (∗) P < 0.05; (n.s.) non-
significant by two-tailed Student t-test.
(C,D) Transposon constructs carrying
NrasG12V cDNA and combinations of two
control shRNAs, one control and one tar-
geting Arid1b (shAR.1), one control and
one targeting Entpd7 (shEN.1), one control
and one targeting Slc31a2 (shSL.2), and
a combination of Entpd7 and Slc31a2
shRNAs (shEN.1 + shSL.2) were delivered
into mouse livers by hydrodynamic injec-
tion. In this experiment, a more active
transposase (SB100) that allows integration
of multiple shRNAs was used. n = 3 mice
per condition were used. Livers were har-
vested after 9 d, and sections were stained
for Nras, Ki67, and SA-β-Gal. Representative pictures of IHC for Nras and SA-β-Gal staining are shown. Quantification of the staining
is shown at the bottom. Bar, 100 μm. Graphs represents mean ± SD. (∗∗∗) P < 0.001; (∗∗) P < 0.005; (∗) P < 0.05; (n.s.) nonsignificant by
two-tailed Student t-test.
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analysis predicts that some ENTPDs, such as ENTPD5
and ENTPD7, will reside inside cells and not at their sur-
face (Robson et al. 2006). Therefore, these ENTPDs could
affect the intracellular pools of nucleotides, as shown pre-
viously for ENTPD5 (Fang et al. 2010).
To investigate the localization of ENTPD7, given the
lack of reliable antibodies, we generated an HA-tagged
ENTPD7 version. ENTPD7 localized intracellularly to
the Golgi apparatus (Fig. 7E; Supplemental Fig. S8D), in
contrast to ENTPD5,which has been described as residing
in the ER (Fang et al. 2010). In agreement with its localiza-
tion, ENTPD7 expression resulted in decreased intracellu-
lar dNTP levels in IMR90 cells (Fig. 7F; Supplemental Fig.
S8E). Conversely, ENTPD7 knockdown prevented the
decrease of dNTPs levels observed during OIS (Fig. 7G;
Supplemental Fig. S8F). Interestingly, ectopic expression
of ARID1B also affected dNTP levels (particularly dTTP
and dATP) in a manner similar to ENTPD7 (Fig. 7F,G;
Supplemental Fig. S8E,F). Consistent with this, IPA sug-
gested an association betweenARID1B expression and py-
rimidine metabolism (Supplemental Fig. S8C).
Based on these observations, we decided to test whether
nucleotide metabolism could constitute a liability of
ARID1B-deficient cells and potentially of SWI/SNF mu-
tated tumors (Supplemental Fig. S9A). We expressed
ENTPD7 in IMR90 ER:RAS cells infected with a control
vector or shRNAs targetingARID1B or p53 (Supplemental
Fig. S9B). Expression of ENTPD7 significantly affected the
growth of ARID1B-depleted but not p53-depleted cells.
The experiment suggested that targeting nucleotide me-
tabolism could be a liability of ARID1B-depleted cells.
To directly test this possibility, we took advantage of 6-
diazo-5-oxo-L-norleucine (DON) and gemcitabine, two
drugs inhibiting nucleotide metabolism (Barclay et al.
1962; Wang et al. 2009). Treatment with 5 µM DON did
not affect the growth of IMR90 ER:RAS control cells or
Figure 7. ARID1B-deficient cells are sensitive to alterations in nucleotide metabolism. (A) ENTPD7 differential expression between
SWI/SNF or ARID1B mutant/wild-type samples was calculated using Student’s t-test (details are in the Materials and Methods) using
The Cancer Genome Atlas Liver Hepatocellular Carcinoma data set. (B) Colony formation assay (top), SA-β-Gal staining (middle), and
BrdU IF (bottom) of IMR90 transduced with an empty vector or cDNA of ARID1B or ENTPD7. Bar, 30 μm. (C ) Quantification by HCA
of BrdU IF and SA-β-Gal staining is shown. n = 3. (D) Quantification by HCA of IF staining for p53, p21CIP1, p16INK4a, 8-oxodG, and
γH2AX in IMR90 cells transduced with ENTPD7 cDNA or empty vector. n = 3. (E) Representative images of HA tag IF staining of
IMR90 cells transduced with either an empty vector or an HA-tagged ENTPD7 cDNA. DAPI was used to visualize the nuclei. Bar, 10
μm. (F ) IMR90 cells were transducedwith either an empty vector,ARID1B cDNA, or ENTPD7 cDNA, and then intracellular dNTP levels
were measured. (G) IMR90 ER:RAS cells were transduced with either an empty vector, an ARID1B shRNA, or an ENTPD7 shRNA and
induced to undergo senescence by 4OHT treatment (+). Intracellular dNTP levels were measured 5 d after 4OHT. (H,I ) Cell growth assay
(H, crystal violet) and SA-β-Gal staining (I ) of stable ARID1B knockdown, p53 knockdown, or control IMR90 ER:RAS cells treated with
4OHT followed by 5 µM 6-diazo-5-oxo-L-norleucine (DON) or DMSO. For H and I, the left panels show representative images, and the
right panels show quantification. Graphs represent mean ± SD from n = 2 (H) and n = 3 (F,G,I ). (∗∗∗) P < 0.001; (∗∗) P < 0.005; (∗) P < 0.05;
(n.s.) nonsignificant by two-tailed Student t-test.
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p53-depleted cells but significantly arrested ARID1B-de-
pleted cells (Fig. 7H). Similar effects were observed when
cells were treated with 5 µM gemcitabine (Supplemental
Fig. S9C). Importantly, the growth arrest in ARID1B-de-
pleted cells was associated with induction of senescence
(Fig. 7I), suggesting that targeting nucleotide metabolism
could be used as a prospective prosenescence therapy
against ARID1B mutant tumors
Discussion
Sequencing cancer genomes is providing us with precise
information on the recurrent genetic alterations present
in different tumor types. Despite this progress, our knowl-
edge of how some of thesemutations affect cancer has not
advanced at a similar rate due to the lack of functional in-
formation. Since bypass of senescence is a common fea-
ture of cancers, we interrogated the ability of genes
frequently deleted in HCC to regulate senescence.
In a genetic screen, we identified the SWI/SNF com-
ponent ARID1B as a regulator of senescence. Other mem-
bers of the SWI/SNF complex have been linked previously
with senescence, including SNF5, BRD7, and BRG1
(Oruetxebarria et al. 2004; Chai et al. 2005; Burrows
et al. 2010; Drost et al. 2010). Interestingly, ablation of
ARID1B in vivo prevents OIS, results in increased prolif-
eration of hepatocytes expressing oncogenic NrasG12V,
and cooperates in oncogenic transformation. Regulation
of p16INK4a and p21CIP1 are two suggested mechanisms
by which SWI/SNF complexes control senescence (Oruet-
xebarria et al. 2004; Chai et al. 2005). In addition to down-
regulating the expression of both CDK inhibitors, manip-
ulating ARID1B levels also affects oxidative stress and
DDR. Taking this into consideration, we screened for
additional ARID1B targets mediating senescence. Our re-
sults suggest that SWI/SNF induces senescence not only
by controlling p16INK4a and p21CIP1 expression but also
via the coordinated regulation of other genes, including
ENTPD7, SLC31A2, and NDST2. Notably, these three
novel regulators of senescence identified here have in
common that, by affecting DDR or oxidative stress,
they could contribute to the activation of the p53/p21
axis.
Due to the high frequency of mutations on SWI/SNF
components, there is a strong interest in developing ther-
apies to target these cancers. Studies looking into vulner-
abilities of ARID1A and BRG1 mutant cancers have
proposed to target residual SWI/SNF complexes in what
has been termed “cancer-selective paralog dependency”
(Helming et al. 2014b; Hoffman et al. 2014). Other thera-
pies for ARID1A-mutated cancers include inhibition of
EZH2 (Bitler et al. 2015), PI3K (Samartzis et al. 2014; Bitler
et al. 2015), or PARP (Shen et al. 2015). However, there is
still the need to identify therapies that could target the
whole spectrum of SWI/SNF mutant tumors. Recently,
treatments that invoke a senescence response (so-called
prosenescence therapies) have been tested against several
tumor types (Nardella et al. 2011; Acosta and Gil 2012).
Since senescence is central to the tumor suppressor prop-
erties of SWI/SNF, we took advantage of the gainedmech-
anistic insights explaining how ARID1B regulates
senescence to target ARID1B-depleted cells. Among the
ARID1B targets, we singled out ENTPD7, an enzyme in-
volved in nucleotidemetabolism.Nucleotidemetabolism
has been linked previously with DDR activation and ulti-
mately OIS (Aird et al. 2013). Cells with reduced ARID1B
expression underwent a strong senescence arrest in re-
sponse to ENTPD7 expression or treatment with inhibi-
tors of nucleotide metabolism (Fig. 7). It could be argued
that this response would imply intact p53 signaling. Inter-
estingly, some studies have highlighted mutual exclusiv-
ity between SWI/SNF and p53 mutations (Guan et al.
2011; Kadoch et al. 2013). Although the connection be-
tween SWI/SNF and p53 is complex, our results suggest
a functional overlap between both pathways that could ex-
plain their mutual exclusivity in cancer (Supplemental
Fig. S9B). In turn, the wild-type p53 status of a significant
subset of SWI/SNFmutant tumors will make it more sen-
sitive to nucleotide metabolism inhibitors.
In conclusion, we identified ARID1B as a gene com-
monly altered in HCC with the ability to control senes-
cence. Regulation of senescence could explain in part
the role of SWI/SNF in tumor suppression. By unveiling
novel pathways regulated by SWI/SNF in senescence,
our investigation suggests novel therapeutic targets,
such as nucleotide metabolism, that could be relevant to
treat tumors deficient in ARID1B and, by extension, other
SWI/SNF components.
Materials and methods
Cell culture and retroviral and lentiviral infection
HEK-293T and IMR90 cells were obtained from American Type
Culture Collection. MEFs were prepared as described in the Sup-
plemental Material. Cell lines were grown and infected with ret-
roviral or lentiviral vectors as described in the Supplemental
Material.
BrdU incorporation, crystal violet staining,
and SA-β-gal staining
BrdU incorporation, crystal violet staining, and SA-β-gal staining
have been described previously (Banito et al. 2009; Barradas et al.
2009; Debacq-Chainiaux et al. 2009; Acosta et al. 2013).
Soft agar assay
RasV12G-infectedMEFs were suspended in complete DMEM con-
taining 0.35% agar (Sigma), seeded in triplicate on six-well plates
precoated with 0.7% agar in complete growthmedium, and incu-
bated at 37°C and 5% CO2. After 21 d, colonies were photo-
graphed and counted in 10 randomly chosen fields.
Gene expression analysis
Total RNA was extracted using Trizol reagent (Invitrogen) and
the RNeasy isolation kit (Qiagen). cDNAs were generated using
SuperScript II reverse transcriptase (Invitrogen), dNTPs, and ran-
domhexamers. PCR reactionswere performed in a real-time PCR
detection system (Bio-Rad) using Power SYBR Green master mix
or TaqMan universal PCR master mix (Applied Biosystems). Ex-
pression was normalized to ribosomal protein S14 (RPS14)
Tordella et al.
10 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 20, 2016 - Published by genesdev.cshlp.orgDownloaded from 
expression. The primer sets used are in Supplemental Table S3.
Mouse tissue samples were weighed and ground to a fine powder
in liquid nitrogen. The RNAwas then extracted and processed as
described above.
In vivo senescence and tumorigenesis experiments
For all animal experiments, only mice in a C57BL/6 background
were used (equal gender distribution in randomized groups).
C57BL/6 mice were purchased from Charles River. At day 0,
HDTV injection of a transposon-based Nras expression plasmid
together with an expression plasmid for sleeping beauty 13 was
performed, as described in detail previously (Kang et al. 2011). An-
imals were sacrificed, and livers were collected at specific time
points (days 6 and 9) or, in the tumorigenesis study, when termi-
nation criteriawere fulfilled. Samples were fixed and subjected to
immunohistochemistry analysis as described in the Supplemen-
tal Material. The antibodies used are in Supplemental Table S4.
No statistical method was used to predetermine sample size.
The investigators were not blinded to allocation during experi-
ments and outcome assessment. Allmiceweremaintained under
specific pathogen-free conditions in accordance with the institu-
tional guidelines of the University of Tübingen. The German le-
gal authorities approved these experiments.
Immunofluorescence (IF) and high-content analysis (HCA)
IFwas performed as described previously (Banito et al. 2009) using
the antibodies in Supplemental Table S4. Details of HCA, IF in
mouse tissue, and confocal microscopy are in the Supplemental
Material.
Statistical analysis
All statistical analyses were performed by two-tailed Student t-
test unless stated otherwise.
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